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Abstract
Objective. The objective of this medication utilization evaluation (MUE) was to determine the appropriateness of
dabigatran and rivaroxaban while also reviewing outcomes for safety and effectiveness within a large, multi-center health
system.
Methods. A retrospective chart review was performed using the system’s electronic medical record. A data inquiry was
requested and generated for dabigatran usage from July 28, 2011 through July 28, 2012 and for rivaroxaban from March
1, 2012 to July 31, 2012 at eight health system hospitals. All patients receiving at least one dose were eligible for
inclusion in the MUE.
Results. For dabigatran, 78 of 390 unique patient encounters were analyzed (20%). All 62 rivaroxaban encounters were
included in the analysis. Dabigatran was used for appropriate indications in 94% of encounters and 82% for rivaroxaban.
Based on indication and renal function, 87% of dabigatran patients and 92% of rivaroxaban patients received correct
dosing. For patients transitioning to or from another anticoagulant, appropriate transitions occurred in 44% of dabigatran
transitions and 48% of rivaroxaban transitions. At discharge, 83% of dabigatran and 86% of rivaroxaban therapy was
continued. There were no reported strokes or systemic embolism with dabigatran, but one reported deep vein thrombosis
occurred during hospitalization with rivaroxaban therapy. Documented bleeds in 5% of dabigatran and 3% of rivaroxaban
patients. Patient education was documented for 37% of dabigatran and 26% of rivaroxaban patients receiving therapeutic
anticoagulation.
Conclusion. This MUE revealed the appropriate use of dabigatran and rivaroxaban therapy with few safety outcomes
within a large, multi-center health system.
The efficacy of dabigatran was demonstrated in
Introduction
New oral anticoagulants have created excitement
the Randomized Evaluation of Long-Term
as potential replacements for warfarin therapy in the
Anticoagulation Therapy (RE-LY) trial comparing
treatment and prevention of thromboembolism. In 2010,
dabigatran against warfarin in the prevention of stroke
dabigatran etexilate (Pradaxa®), an oral direct thrombin
and systemic embolism in non-valvular atrial fibrillation.
inhibitor, received Federal Drug Administration (FDA)
Dabigatran 150 mg by mouth twice daily was superior to
approval for the prevention of stroke and systemic
warfarin therapy in reduction of stroke and systemic
embolism in patients with non-valvular atrial fibrillation.1
embolism, but the incidence of major bleeding was
In 2011, rivaroxaban (Xarelto®) was FDA approved as the
similar.4 Rivaroxaban demonstrated non-inferiority to
first oral factor Xa inhibitor for the reduction of stroke
warfarin in the reduction of stroke and systemic embolism
and systemic embolism in patients with non-valvular
in patients with non-valvular atrial fibrillation in the
atrial fibrillation and for post-operative venous
Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition
thromboembolism (VTE) prophylaxis in patients
Compared with Vitamin K Antagonism for Prevention of
2
undergoing knee and hip replacement surgery.
Stroke and Embolism Trial in Atrial Fibrillation
Additionally, in 2012, rivaroxaban received FDA
(ROCKET AF).5 For VTE prophylaxis, as shown in the
approval for the treatment of deep-vein thrombosis (DVT)
Regulation of Coagulation in Orthopedic Surgery to
and pulmonary embolism (PE).3 The new oral
Prevent Deep Venous Thrombosis and Pulmonary
anticoagulants are appealing alternatives to current
Embolism (RECORD) trials, rivaroxaban illustrated
standard therapy, with demonstrated non-inferiority for
superiority over enoxaparin in the prevention of DVT, PE,
thromboembolic indications and less stringent
and mortality in patients undergoing total hip arthroplasty
monitoring.4-11
(THA) and total knee arthroplasty (TKA). 6-9 The
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EINSTEIN investigators exemplified rivaroxaban noninferiority to warfarin for the initial and continued
treatment of DVT and PE events with similar bleeding
risks.10,11 The manufacturer recommended dosing for
approved indications is listed in Table 1.1,2
With the advent of these new agents, transitions
between anticoagulants hold the potential for serious
medication errors. Appropriate transitions between
agents are essential to optimize care and reduce morbidity
and mortality. Conversion to or from dabigatran or
rivaroxaban requires monitoring and caution is necessary
to minimize thromboembolic and bleeding complications.
Table 1 provides the manufacturer recommended
transitions between available anticoagulants.1,2
Lastly, while both dabigatran and rivaroxaban
have shown efficacy in reducing the risk of systemic
thromboembolism, potential side effects, including
bleeding, are an inherent risk with these medications. The
Adverse Events Reporting System (AERS) database has
noted bleeding as a commonly reported complication with
dabigatran and rivaroxaban therapy.12,13
Dabigatran and rivaroxaban were added to the
Indiana University Health system formulary with orderset
development on March 1, 2011 and March 1, 2012,
respectively. Upon addition to the formulary, both
medications required a mandatory orderset to initiate
therapy due to the inherent risks associated with
anticoagulant therapy. A medication utilization
evaluation (MUE) was performed at eight hospitals within
the large multi-center health system. The primary
objective of this MUE was to determine the
appropriateness of dabigatran and rivaroxaban use while
also reviewing potential outcomes for safety and
effectiveness within a large, multi-center health system.
Methods
A retrospective chart review was performed using
the system’s electronic medical record (EMR). A data
inquiry was requested and generated for dabigatran usage
from July 28, 2011 through July 28, 2012 and for
rivaroxaban from March 1, 2012 to July 31, 2012 at eight
IUH hospitals. Search terms for the inquiry included
“dabigatran”, “Pradaxa®”, “rivaroxaban”, and “Xarelto®.”
All dosage strengths for each anticoagulant were included
in this chart review. Patients receiving at least one dose
during their hospital stay were eligible for inclusion. An
online random number generator was used to select
dabigatran encounters for review. IRB approval was
obtained from Indiana University.
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Data extracted from the EMR included patient
demographics (age, weight, and baseline renal function),
indication, utilization prior to admission, inpatient dosage
strength, number of doses administered, appropriateness
of dose, assessment for appropriate monitoring of
laboratory data, transitioning between anticoagulants,
discharge regimen, reason for discontinuation,
documented thromboembolism or bleeding, and
documentation of anticoagulant education. The indication
for use was collected from provider clinical notes and was
evaluated for appropriateness based on FDA approved
indications at the time of the study period. Utilization
prior to admission was gathered from the admission note
or admission medication history. The inpatient dose was
defined as the dose most frequently received by the
patient during hospitalization. Doses were evaluated as
appropriate based on renal function and manufacturer
recommended dosing for prophylactic or therapeutic
indications. Specific reasons for discontinuation,
documented bleeding, and thromboembolic events were
collected from practitioners’ clinical notes in the EMR.
Based on system protocols, appropriate
monitoring was defined as baseline hemoglobin and at
least once weekly and serum creatinine at baseline and at
least every four days. Serum creatinine was used to
assess renal function by calculation of the creatinine
clearance (CrCl) utilizing the Cockcroft-Gault equation.
Dosing was considered appropriate based on the dosing
adjustments recommended by the manufacturers in Table
1. Transitional therapy between anticoagulants was
evaluated utilizing the electronically reported medication
administration times documented by nursing staff.
Transitions were determined appropriate and
inappropriate utilizing manufacturer recommended
transitions (Table 1).1,2 Concomitant administration of
antiplatelet agents was not considered duplicate
anticoagulation. Statistical analysis was performed using
descriptive statistics.
Results
The data query produced 390 dabigatran orders
with 20% (n=78) encounters analyzed. The query
resulted in 62 rivaroxaban encounters and all rivaroxaban
patient data was reviewed (n=62). Baseline characteristics
are listed in Table 2.
When assessing use prior to hospital admission,
62% (n=48) of dabigatran patients and 24% (n=15) of
rivaroxaban patients were receiving the medication as an
outpatient. According to package labeling at the time of
the study, use for appropriate indications occurred in 94%
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(n=73) of dabigatran and in 82% (n=51) of rivaroxaban
encounters. Indications for use of dabigatran and
rivaroxaban are shown in Table 3. It is worth noting that,
38% of the off-label uses during hospitalization were
continuation of home therapy occurring in four of five
dabigatran and two of eleven rivaroxaban encounters.
Information on inpatient dosing is provided in
Table 4. Based on indication along with renal function,
87% (n=68) of dabigatran patients and 92% (n=57) of
rivaroxaban patients received correct dosing per the
manufacturer.1,2 Continuation of home doses occurred in
60% (n=9) of the incorrect dosing encounters with seven
out of ten incorrect for dabigatran and two out of five for
rivaroxaban. Inappropriate renal adjustment was the
cause of all incorrect dabigatran doses and 80% (n=4) of
incorrect rivaroxaban dosing encounters. Appropriate
hemoglobin and serum creatinine monitoring occurred in
97% (n=76) of dabigatran encounters and 87% (n=54) for
rivaroxaban.
While the dosing was appropriate for a majority
of patients, there were concerns with the transitions
between the new oral anticoagulants and conventional
anticoagulants (Figure 1). For dabigatran, transitioning to
or from another anticoagulant occurred in 46% (n=36) of
patients with only 44% (n=16) appropriate.1 There were
37% of encounters (n=23) in which patients were
transitioned between another anticoagulant and
rivaroxaban. Of the 23, there were 48% (n=11) with
correct transitions as recommended by the manufacturer.2
At discharge, 83% (n=65) of dabigatran and 86%
(n=53) of rivaroxaban therapy was continued. For patients
being discharged on dabigatran, 94% (n=61) had
dabigatran prescribed for an FDA approved indication
and 91% (n=59) had correct dosing based on indication
and renal function. Rivaroxaban patients upon discharge
had an FDA approved indication in 85% of encounters
(n=45) and 94% (n=50) had correct dosing based on
indication and renal function.
For patients with therapy discontinued prior to
discharge, reasons included: transitioning to other
anticoagulants, worsening renal function, death,
thromboembolic and bleeding complications, and
completion of anticoagulant therapy. There were no
reported strokes or systemic embolism in patients
receiving dabigatran. There was one death in a patient
receiving dabigatran, but the death was contributed to
pulmonary complications unrelated to dabigatran therapy.
One VTE occurred during hospitalization in patients
receiving rivaroxaban therapy. Bleeding resulted in the
discontinuation of therapy in three dabigatran and one
JHPR.org

rivaroxaban patients, but there were documented bleeds in
5% (n=4) of dabigatran patients and 3% (n=2) of
rivaroxaban patients. Patient education prior to discharge
was performed for 37% (n=29) of dabigatran encounters
and 26% (n=8) of rivaroxaban patients receiving
therapeutic doses.
Discussion
With any new medication release, post-marketing
surveillance is crucial to evaluate its use within clinical
practice along with potential safety and effectiveness
outcomes. The recent Anticoagulation Forum consensus
statement recommends monitoring of quality indicators to
assess patient outcomes and identify areas for
improvement.14 Due to the intrinsic bleeding risks and
potential for thromboembolic events, the new oral
anticoagulants must be assessed in a clinical setting. This
combined MUE for dabigatran and rivaroxaban reviewed
the utilization of these new oral anticoagulants within a
large, multi-center health system.
Overall, dabigatran and rivaroxaban therapy were
prescribed and dosed appropriately in the majority of
patients. These anticoagulants were used for FDA
approved indications in 89% of encounters. It is worth
noting that during the study period, rivaroxaban had not
yet received FDA indication for the treatment of DVT or
PE. Treatment with rivaroxaban for these indications was
deemed inappropriate for this MUE. Additionally, similar
safety profiles were revealed for dabigatran and
rivaroxaban, when compared to larger clinical trials.4-11
Non-major bleeding complications occurred in 5% of
non-valvular atrial fibrillation patients on dabigatran, less
than the 30% of patients who reported major or minor
bleeding in the RE-LY trial.4 Rivaroxaban bleeding
occurred in 3.2% of patients in this study, with one patient
status post TKA and the other with atrial fibrillation. This
is comparable to the 3.3-6.6% of combined major and
minor bleeding in the RECORD trials and less than the
14.9% seen in the ROCKET-AF.5-9 Bleeding
complications were likely lower than reported in clinical
trials due to the retrospective surveillance used in this
chart review, as compared to extensive observation during
the RE-LY and ROCKET-AF trials.
Excluding bleeding events, few other
complications occurred in patients evaluated for this
MUE. There was one documented death for a patient
receiving dabigatran, but this was contributed to
pulmonary complications unrelated to dabigatran use.
There were no reports of stroke or systemic embolism
during hospitalization in the dabigatran arm and one
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report of a post-operative DVT in a patient receiving
prophylactic rivaroxaban. This encounter lead to a
similar VTE rate, when compared to the incidence in the
four RECORD trials (3.6% vs. 1-10% respectively).6-9
Appropriate transitions between anticoagulant
therapies are imperative to reduce the risk of
thromboembolism and bleeding and this MUE revealed
concerns in transitioning between anticoagulants. While
delays in therapy during a transition between agents
occurred with both anticoagulants, no delays resulted in a
thromboembolism. Inappropriate transitions from this
MUE revealed dual anticoagulants and administration of
new anticoagulants too soon after discontinuation of
previous therapy, enhancing the bleeding risk. This was
demonstrated as one of the rivaroxaban minor bleeds
occurred in a patient where rivaroxaban therapy was
initiated six hours after receiving enoxaparin. Since
practitioners often have less experience with these new
anticoagulants, it is vital to educate on proper transitions
between anticoagulants to enhance the safety and
effectiveness of dabigatran and rivaroxaban.
Finally, due to potential bleeding and
thromboembolic complications inherent with all
anticoagulants, patient counseling is imperative. The
overall rate of anticoagulation patient education for
therapeutic indications for both anticoagulants was only
34% in this MUE. The Joint Commission recommends
patient education for all therapeutic anticoagulants prior
to discharge.14 Additionally, the Anticoagulation Forum
stresses the importance of patient education counseling to
enhance the safe and effective use of these anticoagulants
in the post-discharge process.15 Patient education in the
hospital setting is vital to ensure appropriate utilization
and understanding of these medications. Educational
instructions may include proper medication
administration, compliance, monitoring, drug and food
interactions, and potential adverse reactions from
anticoagulant therapy. Patient education continues to be a
focus for pharmacists to ensure patients are adequately
informed of their therapy, potentially minimizing
thromboembolic and bleeding complications.
This MUE is the first to evaluate the use of these
medications within a large, multi-center health system;
however, it is not without limitations. Due to the large
number of patients receiving dabigatran, encounters were
randomly selected and not all patients who received doses
were reviewed in this analysis. Patients were only
considered for inclusion if they had an order for
dabigatran or rivaroxaban. Therefore, all bleeding and
thromboembolic complications may not have been
JHPR.org

evaluated as there could have been patients who had the
medication held or discontinued during their entire
hospitalization. Also, the indication and continuation of
home therapy was dependent upon reliable clinical notes
and admission medical histories. Furthermore, no subgroup analysis was performed to identify risk
characteristics for the safety and efficacy outcomes.
Lastly, with the retrospective nature of this study, there
was no follow-up assessment after hospital discharge,
making it difficult to determine the true bleeding and
thromboembolic complications.
As a result of this MUE, health system changes
were implemented to improve the safe and effective use
of these oral anticoagulants. The orderset for both of
these anticoagulants was updated to reinforce the FDA
approved indications and dosing, along with manufacturer
recommended transitions between anticoagulants. To
increase patient education, an alert was built to notify
pharmacists to educate patients on these new oral
anticoagulants prior to discharge. Continued evaluation
of patients on these oral anticoagulants will determine the
final impact of this MUE on the health-system.
Conclusion
This medication utilization evaluation within a
large, multi-center health system focused on the
utilization of dabigatran and rivaroxaban therapy.
Anticoagulant therapy was appropriate for most
encounters, utilizing FDA approved indications and
dosing recommendations. In addition, rates of bleeding
and thromboembolism were less than or similar compared
to clinical trials. However, quality improvement efforts
have been implemented to improve the appropriate and
safe use of these anticoagulants. Overall, this medication
utilization evaluation revealed the appropriate use of
these new oral anticoagulants within this health system
with few safety outcomes.
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Table 1: Dosing and Transitions between Anticoagulants
Dabigatran1
Dosing Recommendations
Non-valvular
 CrCl > 30 mL/min: 150 mg orally BID
atrial fibrillation  CrCl 15-30 mL/min: 75 mg orally BID
TKA/THA
post-operative
prophylaxis

Rivaroxaban2
 CrCl > 50 mL/min: 20 mg orally daily
 CrCl 30-50 mL/min: 15 mg orally daily
 CrCl > 30 mL/min: 10 mg orally daily
 CrCl > 50 mL/min: 15 mg orally BID
for 3 weeks then 20 mg orally daily
 CrCl 30-50: 15 mg orally BID for 3
weeks then 15 mg orally daily

DVT/PE
Treatment
Anticoagulation Transitioning
 From warfarin, discontinue warfarin must
be discontinued and initiate dabigatran
started when INR < 2.0
 To warfarin:
Warfarin
o CrCl > 50 mL/min: discontinue
dabigatran 3 days after starting warfarin
o CrCl of 31-50 mL/min: discontinue
dabigatran 2 days after starting warfarin
o CrCl of 15-30 mL/min: discontinue
dabigatran 1 day after starting warfarin
 From UFH, initiate dabigatran at the time
of UFH discontinuation
 To UFH, discontinue dabigatran and
initiate UFH based on estimated CrCl:
UFH
o CrCl > 30 mL/min: wait 12 hours after
last dose of dabigatran
o CrCl 15-30 mL/min: wait 24 hours
after last dose of dabigatran
 From another parenteral anticoagulant,
start dabigatran within 2 hours of next
scheduled dose of the discontinued agent
 To another parenteral anticoagulant,
Other parenteral
discontinue dabigatran and initiate the
anticoagulants
anticoagulant based on estimated CrCl:
o CrCl > 30 mL/min: wait 12 hours after
last dose of dabigatran
o CrCl 15-30 mL/min: wait 24 hours
after last dose of dabigatran

 From warfarin, discontinue warfarin
and start rivaroxaban when INR < 3.0
 To warfarin, initiate warfarin 24 hours
after discontinuing rivaroxaban and
bridge with a parenteral anticoagulant
until INR is therapeutic

 From UFH, rivaroxaban therapy should
be started once the UFH infusion has
been stopped
 To UFH, begin the continuous infusion
UFH 24 hours after stopping the
rivaroxaban
 From another parenteral anticoagulant,
initiate rivaroxaban within 2 hours of
the next scheduled dose of the
discontinued agent
 To another parenteral anticoagulant,
begin the anticoagulant 24 hours after
stopping rivaroxaban

CrCl = creatinine clearance; BID = twice daily; TKA = total knee arthroplasty;
THA = total hip arthroplasty; DVT = deep vein thrombosis; PE = pulmonary embolism;
INR = international normalized ratio; UFH = unfractionated heparin
JHPR.org
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Table 2: Baseline Characteristics

Mean age – years (SD)
Male sex – n (%)
Weight, kg – median (IQR)
Creatinine Clearance – n (%)
>50 mL/min
30-50 mL/min
< 30 mL/min

Dabigatran
Encounters
(n=78)
66.9 ± 13.7
39 (50)
87 (72-99)

Rivaroxaban
Encounters
(n=62)
62.8 ± 13.7
33 (53)
94 (77-103)

55 (70.5)
16 (20.5)
7 (9)

43 (69)
16 (26)
3 (5)

SD = standard deviation; IQR = interquartile range

Table 3: Indications for Use*
Dabigatran
Encounters
(n=78)
% (n)

Rivaroxaban
Encounters
(n=62)
% (n)

93 (73)
-

37 (23)
39 (24)
6 (4)

7 (5)
-

8 (5)
3 (2)
2 (1)
2 (1)
2 (1)
2 (1)

FDA Approved Indications
Non-valvular atrial fibrillation
Post-operative prophylaxis TKA
Post-operative prophylaxis THA
Non-FDA Approved Indications
Prevention of recurrent VTE
Open reduction internal fixation prophylaxis
Peripheral vascular disease
DVT treatment
Paroxysmal supraventricular tachycardia
Genetic coagulopathies
Incision and drainage

TKA = total knee arthroplasty; THA = total hip arthroplasty; VTE = venous thromboembolism; DVT =
deep vein thrombosis
*FDA approved indications at the time of analysis (July 2012)
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Table 4: Dose and Dosing Adjustments

Doses administered per patient
Mean
Median (IQR)
Anticoagulant orders, % (n)

Doses administered, % (n)

Dabigatran
Encounters

Rivaroxaban
Encounters

6.4
5 (3-7)
75 mg BID
83 (65)
150 mg BID
16 (12)
150 mg TID
1 (1)
75 mg
22 (107)
150 mg
78 (387)

3.2
3 (2-4)
10 mg daily
55 (34)
15 mg daily
21 (13)
20 mg daily
24 (15)
10 mg
110 (56)
15 mg
37 (19)
20 mg
50 (25)
92 (57)
79 (15)

Appropriate dose, % (n)
Appropriate renal dose adjustment, % (n)

87 (68)
55 (6)

Figure 1: Transitioning Between Anticoagulant Therapy
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